Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urgency Frequency Clear all

Conditions: Urinary Frequency, Urinary Urgency, Nocturia
Interventions: Solifenacin PO; Drug
Lead sponsor: Seattle Urology Research Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Incontinence
Interventions: Current Perception Threshold (CPT) Testing; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions: iStim TENS unit and Transvaginal Probe; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urgency-frequency Syndrome, Urinary Incontinence, Urinary Incontinence, Urge
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions: Axonics SNM System; Device
Lead sponsor: Axonics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more

Conditions: Overactive Bladder
Interventions: (VERV™ System), Sham version of (VERV™ System); Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 14
States / cities: Tucson, Arizona • Murrieta, California • Washington D.C., District of Columbia + 11 more

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, tamsulosin, placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more

Conditions: Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Interventions: Fesoterodine, fesoterodine plus fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Overactive Bladder
Interventions: Tolterodine ER, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Interstitial Cystitis
Interventions: Dexmedetomidine, Normal Saline; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Bladder Pain and Discomfort, Urinary Urgency and Frequency, Bothersome Symptoms
Interventions: Pain sensitivity testing, Urodynamic testing; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Overactive Bladder, Bladder, Overactive, Urge Incontinence, Urgency Urinary, Urinary Frequency/Urgency
Interventions: Transvaginal botulinum toxin A (BTA) injection; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 82
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 109
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urinary Urge Incontinence, Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions: PTNS, TENS; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Urinary Frequency/Urgency
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 22 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Lower Urinary Tract Symptoms, Colorectal Disorders
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Orange, California

Conditions: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Urinary Frequency/Urgency, Urinary Incontinence, Urge, Incontinence, Urinary, Nocturia
Interventions: UroLift as artifical device for prostatic urethral lift., Embospheres Microspheres as embolic agents for prostate artery embolization; Device
Lead sponsor: St. Louis University; Other
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
Interventions: fesoterodine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Desert Harvest Aloe Vera Capsules, Placebo Capsules; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
Interventions: Wearable Bladder Modulation System; Device
Lead sponsor: Avation Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Stanford, California • Denver, Colorado • Englewood, Colorado + 6 more

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS), Painful Bladder Syndrome (PBS), Benign Frequency Syndrome (BFS), Interstitial Cystitis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Tolterodine ER 4mg, Placebo, Pre-randomization Dutasteride; Drug
Lead sponsor: Siami, Paul F., M.D.; Other
Eligibility: 50 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Newburgh, Indiana

Search by objective public record fields.

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

CPT Testing for Sacral Neuromodulation Outcomes

TEST-ON - Does iStim Reduce Urinary Urgency?

rTMS in Overactive Bladder

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects

Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder

Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis

Sensory Sensitivity and Urinary Symptoms in the Female Population

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder

Development of Novel Cystometrics for Overactive Bladder

Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders

Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men

This Is A Study Of Bioavailability And Food Effect For Fesoterodine.

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

FREEOAB Study for Overactive Bladder

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)